Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) EBIT (2021 - 2025)

PAVmed (PAVM) has 5 years of EBIT data on record, last reported at -$4.8 million in Q3 2025.

  • For Q3 2025, EBIT changed N/A year-over-year to -$4.8 million; the TTM value through Sep 2025 reached -$20.2 million, changed N/A, while the annual FY2024 figure was -$44.5 million, 35.33% up from the prior year.
  • EBIT reached -$4.8 million in Q3 2025 per PAVM's latest filing, down from -$4.7 million in the prior quarter.
  • Across five years, EBIT topped out at -$4.7 million in Q2 2025 and bottomed at -$24.6 million in Q4 2022.
  • Average EBIT over 5 years is -$14.6 million, with a median of -$14.8 million recorded in 2023.
  • Peak YoY movement for EBIT: crashed 143.1% in 2022, then surged 68.34% in 2024.
  • A 5-year view of EBIT shows it stood at -$19.7 million in 2021, then decreased by 25.01% to -$24.6 million in 2022, then soared by 33.41% to -$16.4 million in 2023, then soared by 68.34% to -$5.2 million in 2024, then increased by 6.63% to -$4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$4.8 million in Q3 2025, -$4.7 million in Q2 2025, and -$5.4 million in Q1 2025.